Eli Lilly reported non-GAAP earnings per share of $7.48, beating analyst expectations of $6.26 by $1.22

Overview Debates Related claims Topics

Eli Lilly increased its full-year 2024 revenue guidance from $85 billion to $87 billion up to a revised range of $91 billion to $92 billion

Eli Lilly's weight-loss drug Zepbound generated $5 billion in quarterly revenue, marking a 50% year-over-year increase

Eli Lilly reported a gross profit margin of 83% for the third quarter of 2024

Oracle announced at its late 2024 investor day that the company does not expect to require substantial external capital raises through 2030

Eli Lilly's diabetes medication Mounjaro generated $10 billion in quarterly revenue, reflecting a 65% year-over-year increase

Robinhood reported quarterly cryptocurrency revenue of $120 million, representing a 20% quarter-over-quarter increase

Robinhood Chain generated approximately $50 million in revenue during its first reported operating quarter

Despite Nvidia reporting earnings and guidance far exceeding estimates, its stock remained unchanged, leading to a P/E multiple compression

The current AI market is not considered a bubble

The stock price of the CME Group declined following news about a potential US-compliant version of Hyperliquid

Micron's new long-term agreements are expected to reduce the cyclicality of its earnings

Micron's earnings came in better than expected, and the company signed new long-term agreements

Meta's Q3 revenue guidance was below the midpoint of expectations

For the past 12 months, public companies have consistently discussed their use of AI on earnings calls

Meta raised the lower end of its capital expenditure (CapEx) guidance by $5 billion

Meta's stock fell 10% following its earnings call where it raised CapEx guidance

Companies can artificially boost earnings per share (EPS) by reducing expenses, having a lower tax rate, or buying back shares

Corporate earnings per share (EPS) and future EPS projections are growing at a high rate